Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Kiniksa Pharmaceuticals International (KNSA) Equity Ratio (2021 - 2025)

Historic Equity Ratio for Kiniksa Pharmaceuticals International (KNSA) over the last 5 years, with Q3 2025 value amounting to 0.75.

  • Kiniksa Pharmaceuticals International's Equity Ratio fell 449.63% to 0.75 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.75, marking a year-over-year decrease of 449.63%. This contributed to the annual value of 0.76 for FY2024, which is 942.45% down from last year.
  • Kiniksa Pharmaceuticals International's Equity Ratio amounted to 0.75 in Q3 2025, which was down 449.63% from 0.75 recorded in Q2 2025.
  • Over the past 5 years, Kiniksa Pharmaceuticals International's Equity Ratio peaked at 0.88 during Q1 2023, and registered a low of 0.72 during Q1 2022.
  • Its 5-year average for Equity Ratio is 0.81, with a median of 0.83 in 2024.
  • In the last 5 years, Kiniksa Pharmaceuticals International's Equity Ratio plummeted by 1726.32% in 2022 and then surged by 2237.77% in 2023.
  • Quarter analysis of 5 years shows Kiniksa Pharmaceuticals International's Equity Ratio stood at 0.79 in 2021, then increased by 8.43% to 0.86 in 2022, then fell by 3.25% to 0.83 in 2023, then dropped by 9.42% to 0.76 in 2024, then dropped by 0.48% to 0.75 in 2025.
  • Its Equity Ratio stands at 0.75 for Q3 2025, versus 0.75 for Q2 2025 and 0.76 for Q1 2025.